CIDARA THERAPEUTICS INC's ticker is CDTX and the CUSIP is 171757107. A total of 42 filers reported holding CIDARA THERAPEUTICS INC in Q3 2017. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $6,082,000 | +12.8% | 2,295,272 | 0.0% | 0.15% | -11.6% |
| Q4 2018 | $5,394,000 | -46.6% | 2,295,272 | 0.0% | 0.17% | -35.2% |
| Q3 2018 | $10,099,000 | -15.4% | 2,295,272 | 0.0% | 0.27% | -22.6% |
| Q2 2018 | $11,935,000 | +30.0% | 2,295,272 | 0.0% | 0.34% | +35.8% |
| Q1 2018 | $9,181,000 | -41.2% | 2,295,272 | 0.0% | 0.25% | -42.3% |
| Q4 2017 | $15,608,000 | +44.3% | 2,295,272 | +71.9% | 0.44% | +47.2% |
| Q3 2017 | $10,816,000 | +30.8% | 1,335,272 | +21.1% | 0.30% | +18.2% |
| Q2 2017 | $8,269,000 | +1.6% | 1,102,578 | +5.6% | 0.25% | -4.9% |
| Q1 2017 | $8,142,000 | -25.0% | 1,043,824 | 0.0% | 0.27% | -33.8% |
| Q4 2016 | $10,856,000 | +27.0% | 1,043,824 | +39.8% | 0.40% | +33.6% |
| Q3 2016 | $8,551,000 | +11.1% | 746,824 | 0.0% | 0.30% | -1.0% |
| Q2 2016 | $7,700,000 | -18.8% | 746,824 | 0.0% | 0.30% | -19.4% |
| Q1 2016 | $9,485,000 | +18.4% | 746,824 | +60.0% | 0.38% | +66.8% |
| Q4 2015 | $8,008,000 | – | 466,679 | – | 0.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERWEST VENTURE MANAGEMENT CO | 1,356,813 | $3,189,000 | 4.48% |
| Omega Fund Management, LLC | 1,508,794 | $3,546,000 | 2.63% |
| ALETHEA CAPITAL MANAGEMENT, LLC | 482,357 | $1,134,000 | 1.65% |
| Opaleye Management Inc. | 1,200,000 | $2,820,000 | 1.05% |
| BVF INC/IL | 2,904,684 | $6,826,000 | 0.89% |
| FRAZIER MANAGEMENT LLC | 1,312,258 | $3,084,000 | 0.80% |
| Monashee Investment Management LLC | 480,851 | $1,130,000 | 0.76% |
| Aisling Capital LLC | 1,021,148 | $2,400,000 | 0.68% |
| Trellus Management Company, LLC | 94,143 | $221,000 | 0.50% |
| Prosight Management, LP | 245,764 | $578,000 | 0.30% |